JP2016533395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533395A5 JP2016533395A5 JP2016546183A JP2016546183A JP2016533395A5 JP 2016533395 A5 JP2016533395 A5 JP 2016533395A5 JP 2016546183 A JP2016546183 A JP 2016546183A JP 2016546183 A JP2016546183 A JP 2016546183A JP 2016533395 A5 JP2016533395 A5 JP 2016533395A5
- Authority
- JP
- Japan
- Prior art keywords
- specific binding
- binding member
- her2
- cancer
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009870 specific binding Effects 0.000 claims 33
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 23
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 12
- 230000027455 binding Effects 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 9
- 101150054472 HER2 gene Proteins 0.000 claims 8
- 108700020302 erbB-2 Genes Proteins 0.000 claims 8
- 239000002299 complementary DNA Substances 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 229960000575 trastuzumab Drugs 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000002860 competitive effect Effects 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 238000003365 immunocytochemistry Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317622.7A GB201317622D0 (en) | 2013-10-04 | 2013-10-04 | Cancer biomarkers and uses thereof |
| GB1317622.7 | 2013-10-04 | ||
| PCT/GB2014/052994 WO2015049537A1 (en) | 2013-10-04 | 2014-10-03 | Cancer biomarkers and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533395A JP2016533395A (ja) | 2016-10-27 |
| JP2016533395A5 true JP2016533395A5 (cg-RX-API-DMAC10.html) | 2018-08-09 |
| JP6449308B2 JP6449308B2 (ja) | 2019-01-09 |
Family
ID=49630223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546183A Expired - Fee Related JP6449308B2 (ja) | 2013-10-04 | 2014-10-03 | がんバイオマーカー及びその使用 |
Country Status (20)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423140T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| PL3241842T3 (pl) | 2007-06-26 | 2024-06-10 | F-Star Therapeutics Limited | Prezentacja środków wiążących |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2016162505A1 (en) * | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019122882A1 (en) * | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| CN107868814A (zh) * | 2017-12-19 | 2018-04-03 | 威海威仕泰医疗科技有限公司 | 一种用于检测HER2基因的Dig标记探针的制备方法 |
| CR20250022A (es) | 2018-04-02 | 2025-02-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450) |
| CN112584862A (zh) * | 2018-05-17 | 2021-03-30 | 伊米若梅有限公司 | Ch3结构域表位标签 |
| CN108875302B (zh) * | 2018-06-22 | 2022-02-22 | 广州漫瑞生物信息技术有限公司 | 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| KR102325731B1 (ko) * | 2020-01-15 | 2021-11-15 | 주식회사 베르티스 | 암의 진단용 조성물 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423140T1 (de) * | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| PL3241842T3 (pl) * | 2007-06-26 | 2024-06-10 | F-Star Therapeutics Limited | Prezentacja środków wiążących |
| EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| US20120121586A1 (en) * | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
-
2013
- 2013-10-04 GB GBGB1317622.7A patent/GB201317622D0/en not_active Ceased
-
2014
- 2014-10-03 AU AU2014330942A patent/AU2014330942A1/en not_active Abandoned
- 2014-10-03 PE PE2016000450A patent/PE20160950A1/es not_active Application Discontinuation
- 2014-10-03 ES ES14781645.8T patent/ES2687783T3/es active Active
- 2014-10-03 CN CN201480055024.5A patent/CN105722997A/zh active Pending
- 2014-10-03 JP JP2016546183A patent/JP6449308B2/ja not_active Expired - Fee Related
- 2014-10-03 DK DK14781645.8T patent/DK3052647T3/en active
- 2014-10-03 WO PCT/GB2014/052994 patent/WO2015049537A1/en not_active Ceased
- 2014-10-03 LT LTEP14781645.8T patent/LT3052647T/lt unknown
- 2014-10-03 EA EA201690450A patent/EA201690450A1/ru unknown
- 2014-10-03 SG SG11201602605TA patent/SG11201602605TA/en unknown
- 2014-10-03 EP EP14781645.8A patent/EP3052647B1/en active Active
- 2014-10-03 CA CA2925186A patent/CA2925186A1/en not_active Abandoned
- 2014-10-03 BR BR112016007348A patent/BR112016007348A2/pt not_active Application Discontinuation
- 2014-10-03 MX MX2016004286A patent/MX2016004286A/es unknown
- 2014-10-03 KR KR1020167011055A patent/KR20160092992A/ko not_active Withdrawn
- 2014-10-03 HR HRP20181566TT patent/HRP20181566T1/hr unknown
-
2016
- 2016-03-08 IL IL244510A patent/IL244510A0/en unknown
- 2016-03-31 US US15/087,272 patent/US20160289336A1/en not_active Abandoned
- 2016-04-04 CL CL2016000777A patent/CL2016000777A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2556091T3 (en) | Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies to treat diseases associated with unwanted cell proliferation | |
| JP2014524746A5 (cg-RX-API-DMAC10.html) | ||
| DK3052647T3 (en) | BIOMARKERS FOR CANCER AND APPLICATIONS THEREOF | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2015529641A5 (cg-RX-API-DMAC10.html) | ||
| KR102571924B1 (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| JP2021516057A5 (cg-RX-API-DMAC10.html) | ||
| JP2012012402A5 (cg-RX-API-DMAC10.html) | ||
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| DK1937815T3 (en) | Methods and compositions for the modulation of tumor cell activity | |
| JP2015533788A5 (cg-RX-API-DMAC10.html) | ||
| JP2019511904A5 (cg-RX-API-DMAC10.html) | ||
| JP2016536330A5 (cg-RX-API-DMAC10.html) | ||
| JP2018518152A5 (cg-RX-API-DMAC10.html) | ||
| JP2018511319A5 (cg-RX-API-DMAC10.html) | ||
| JP2017530691A5 (cg-RX-API-DMAC10.html) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2014518615A5 (cg-RX-API-DMAC10.html) | ||
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2016539083A5 (cg-RX-API-DMAC10.html) | ||
| JP2011509246A5 (cg-RX-API-DMAC10.html) | ||
| JP2017538439A5 (cg-RX-API-DMAC10.html) | ||
| CN102099376A (zh) | 针对her2的细胞外结构域2和3的抗体 | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака |